Plain-English translation of NCT06706557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that looks at special markers in the blood of patients with advanced breast cancer that has low HER2 levels. Researchers want to understand how to better detect and monitor this type of cancer by analyzing circulating tumor DNA—pieces of cancer DNA that naturally float in the bloodstream. By studying these blood markers, the research team hopes to develop better ways to track how the disease is progressing.
Currently, doctors have limited tools to monitor HER2-low breast cancer in its advanced stages. This study aims to see whether analyzing blood samples can provide a simpler, less invasive way to track the disease and potentially help guide treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
As a participant, you would visit the European Institute of Oncology to have blood samples taken. The study involves monitoring your health over time to see how the circulating tumor DNA in your blood changes. You would need to be available for follow-up visits, though the exact schedule is not detailed in this record. The main thing you would do is donate blood samples so researchers can analyze them.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Italy
European Institute of Oncology
Enrollment target
~30 participants
Started
January 2024
Primary completion
December 2026
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nicola Fusco, MD
Istituto Europeo di Oncologia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.